Cited by Targeted and combination immunotherapies using biologics for gastric cancer: the state-of-the-art

Targeted therapy and immunotherapy for gastric cancer: rational strategies, novel advancements, challenges, and future perspectives DOI

Dong Luo, Yunmei Liu, Zhengmao Lu

et al.

Molecular Medicine, Journal Year: 2025, Volume and Issue: 31(1)

Published: Feb. 8, 2025

Abstract Gastric cancer (GC) is one of the most common malignant tumors worldwide, and its treatment has been a focus medical research. Herein we systematically review current status advancements in targeted therapy immunotherapy for GC, which have emerged as important strategies recent years with great potential, summarize efficacy safety such treatments. Targeted therapies against key targets including epidermal growth factor receptor (EGFR), human 2 (HER2), vascular endothelial (VEGF)/VEGF (VEGFR), shown remarkable therapeutic efficacies by inhibiting tumor progression and/or blood supply. In particular, markable breakthroughs made HER2-targeting drugs HER2-positive GC patients. To address intrinsic acquired resistances to drugs, novel agents bispecific antibodies antibody–drug conjugates (ADC) targeting HER2 developed. Immunotherapy enhances recognition elimination cells activating body anticancer immune system. Programmed cell death protein 1 (PD-1) programmed death-ligand (PD-L1) are commonly used immunotherapeutic some success treatment. Innovative modalities, adoptive therapy, vaccines, non-specific immunomodulators oncolytic viruses promise early-stage clinical trials GC. Clinical supported that can significantly improve survival quality life However, effects need be further improved more personalized, advancement researches on microenvironment. Further studies remain needed issues drug resistance adverse events pertaining The combined application individualized should explored developed, provide effective treatments

Language: Английский

Citations

DNA methyltransferase 3A: A prognostic biomarker and potential target for immunotherapy in gastric cancer DOI

Zhou Wei,

Zhenzhen Kou, Yun Luo

et al.

Medicine, Journal Year: 2025, Volume and Issue: 104(7), P. e41578 - e41578

Published: Feb. 14, 2025

DNA methyltransferase 3A (DNMT3A) has been associated with the occurrence or progression of various tumors, including gastric cancer. However, role DNMT3A in efficacy immune-cell infiltration tumor microenvironment and immunotherapy cancer remains less explored. expression level was analyzed using TIMER 2.0, Sangerbox 3.0, The Cancer Genome Atlas database further verified by immunohistochemical staining RT-qPCR. UALCAN, chi-square test, Kaplan–Meier plotter databases were performed to assess correlation clinicopathological characteristics prognosis. GeneMANIA database, STRING R package used construct a co-expression gene network. Gene set enrichment analysis identify signaling pathways related expression. correlations between immune infiltrates investigated Plotter, package, TISIDB databases. immunomodulators Immune cell Proportion Score. association mutational burden (TMB), microsatellite instability, dryness evaluated TMB function 2.0. Finally, biological cells assessed CCK-8, cloning formation, transwell assay. remarkably upregulated high poor clinical features survival patients Moreover, analyses showed that its genes involved promoted influencing microenvironment. significantly tumor-infiltrating cells, immunomodulators, TMB, checkpoints knockdown reduced proliferation migration cells. Our findings highlight potential as prognosis biomarker an immunotherapeutic target for

Language: Английский

Citations

Identification of molecular therapeutic features of the homeopathy medicine Thuja by genome-wide expression profiling DOI

Chandana Yesudas,

Yoga Soundarya Mohanraj,

J. Saravanan J. Senthil

et al.

Pharmacological Research - Modern Chinese Medicine, Journal Year: 2025, Volume and Issue: unknown, P. 100596 - 100596

Published: March 1, 2025

Language: Английский

Citations

Comparison of immune checkpoint inhibitors in combination with chemotherapy versus chemotherapy alone in the first-line treatment of advanced gastric cancer patients with low PD-L1 expression: a systematic review and meta-analysis DOI

Yuxin Wang,

Tong Xie,

Shuai Xiang

et al.

Therapeutic Advances in Medical Oncology, Journal Year: 2025, Volume and Issue: 17

Published: May 1, 2025

Background: Immune checkpoint inhibitors (ICIs) + chemotherapy became standard her2-GC first line treatment. Objectives: The aim of this study is to investigate whether ICIs chemo provides benefit for patients with low programmed death-ligand 1 (PD-L1) expression. Design: This a systematic review and meta-analysis. Data sources: We searched PubMed, Embase, Web Science, Cochrane Library as well the 2019 2024 Annual Meetings European Society Medical Oncology, American Association Cancer Research, Clinical Oncology (ASCO), ASCO Symposium on Gastrointestinal (ASCO-GI) ClinicalTrials.gov database. Methods: included phase III randomized controlled trials comparing first-line immunotherapy combined versus alone in advanced gastric cancer. KMSubtraction was used estimate survival data those that did not report PD-L1 low-expression population. Results: total nine clinical trials. In positive score (CPS) < CPS 5, monoclonal antibody show an improvement overall (OS) or progression-free (PFS) (CPS OS: hazard ratio (HR) = 0.91, 95% CI: 0.77–1.08; PFS: HR 0.88, 0.73–1.07. 5 0.92, 0.79–1.08; 0.78, 0.53–1.14). However, using dual antibodies, achieved improvements PFS (HR 0.64, 0.52–0.80). tumor area positivity (TAP) scoring, subgroup TAP 5% achieve benefits OS from plus (OS: 0.75–1.13; 0.74–1.13). Conclusion: Our results indicate treatment cancer, does provide compared it noteworthy COMPASSION-15 trial, significant PFS, which may be related bispecific antibodies needs validated by further studies. Trial registration: registered PROSPERO (CRD42024568972).

Language: Английский

Citations

Predictive Factors of Immunotherapy in Gastric Cancer: A 2024 Update DOI

Vasile Bințințan, Claudia Burz,

Irena Pintea

et al.

Diagnostics, Journal Year: 2024, Volume and Issue: 14(12), P. 1247 - 1247

Published: June 13, 2024

Many studies on gastric cancer treatment have identified predictors of immunotherapy benefits. This article provides an update the major developments in research related to predictive factors for cancer. We used search term “predictive factors, immunotherapy, cancer” find most current publications PubMed database Programmed cell death, genetic, and immunological are main study topics immunotherapy’s Other preventive were also found, including clinical tumor microenvironment imaging extracellular factors. Since there is currently no effective cancer, we strongly propose that these be prioritized.

Language: Английский

Citations

Targeted and combination immunotherapies using biologics for gastric cancer: the state-of-the-art DOI

Jane E. Rogers, Qiong Gan, Rebecca Waters

et al.

Expert Opinion on Biological Therapy, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 24, 2024

Gastricadenocarcinoma (GAC) remains a prevalent cancer worldwide and its incidence is increasingin South America. The heterogenous nature of GAC makes advances in managementchallenging.

Language: Английский

Citations